Acute Myeloid Leukemia Market Overview
The global acute myeloid leukemia therapeutics market was valued at approximately USD 615 million and is expected to witness a CAGR of 14% over 2018-2023 (henceforth, the forecast period). The key factors propelling this market are high incidence and prevalence of acute myeloid leukemia, and increasing investments in R&D.
High Incidence and Prevalence of Acute Myeloid Leukemia
Acute Myeloid Leukemia (AML) is very common in adults and accounts for 80% of cases. In the United States, the incidence of AML ranges from three to five cases for a population of 100,000. According to a cancer statistics in 2015, there are 20,830 new cases that are diagnosed and 10,000 have died from this disease. Increasing expenditure on healthcare. According to data from the centers on Medicare and Medicaid Services, the United States spent USD 3.2 trillion on healthcare, in 2015. Additionally, increasing investment in R&D and advancement in pharmacology and molecular biology, to promote drug development, are also driving the global acute myeloid leukemia therapeutics market.
Complications Related to Chemotherapy
Chemotherapy treats various types of cancer. However, it also causes varied side-effects in different patients at different locations, which mainly depend on the type of cancer, location of the cancer, drugs and their dosage, and general health of the individual. The common side-effects of chemotherapy include - headache, muscle pain, stomach pain, and pain from nerve damage, which refers to burning and numbness. Additionally, stringent regulatory guidelines of the government in various countries are restraining the global acute myeloid leukemia therapeutics market.
Market Segmentation Insights for the Acute Myeloid Leukemia Market
Insights on Chemotherapy Segment
Under the Chemotherapy segment, the largest market share is held by Cytarabine in the global market. Apart from finding direct application in Acute Myeloid Leukemia (AML), cytarabine is also used in treatment of acute lymphocytic leukemia (ALL), chronic myelogenous leukemia (CML), and non-Hodgkin's lymphoma. The largest market share of Cytarabine is attributable to the fact that it is a 1st generation chemotherapy drug due to which it has larger user base and adoption rate. However, the Anti-metabolite sub-segment under Chemotherapy segment is expected to show fastest growth due to greater positive response in reported use-cases which is spurring its popularity.
Insights on Geography Segment
Geographically, the market has been segmented into North America, Europe, Asia-Pacific, Middle East & Africa, and South America. North America dominates the acute myeloid leukemia therapeutics market, due to the rising incidence of acute myeloid leukemia therapeutics, rise in the healthcare expenditure in the region, high investments on the development of pipeline drugs, and awareness among the people for the treatment of the acute myeloid leukemia therapeutics. Asia-Pacific is expected to be the fastest growing region over the forecast period.
Key Developments in the Acute Myeloid Leukemia Market
- June 2017: Genmab received the US FDA approval for Darzalex, for the relapsed or refractory multiple myeloma.
Major players: Genmab A/S, GlaxoSmithKline, Bristol Myer Squibb, Novartis AG, Roche, Celegene Corporation, and Eisai Co. Ltd, among others.
Acute Myeloid Leukemia Market Segmentation
Acute Myeloid Leukemia Market by Chemotherapy
- Cytarabine
- Anthracycline Drugs
- Daunomycin
- Idarubicin
- Mitoxantrone
- Alkylating Agents
- Anti-metabolites
- Tyrosine Kinase Inhibitors
- Dasatinib (Sprycel)
- Imatinib (Gleevec)
- Hormonal Therapy
- Others
Acute Myeloid Leukemia Market by Region
- North America
- US
- Canada
- Mexico
- Europe
- France
- UK
- Germany
- Italy
- Spain
- Asia Pacific
- India
- China
- Japan
- Australia
- South Korea
- Middle East and Africa
- GCC
- South Africa
- South America
- Brazil
- Argentina
Country Level Data Points Coverage and Deliverables for Acute Myeloid Leukemia Market
Acute Myeloid Leukemia Market Report Summary
|
Metrics |
Details |
|
Industry |
Acute Myeloid Leukemia Therapeutics Market |
|
Study Period |
(2015 – 2023) |
|
Growth Rate |
14% |
|
Segmentation Scope |
Segmentation by Chemotherapy includes Cytarabine, Anthracycline Drugs (Daunomycin, Idarubicin, and Mitoxantrone), Alkylating Agents, Anti-metabolites, Tyrosine Kinase Inhibitors (Dasatinib, and Imatinib), Hormonal Therapy, and Others; |
|
Regional Scope |
North America (US, Canada, Mexico), Europe (UK, Germany, France, Italy Spain, Rest of Europe), Asia-Pacific (Japan, China, India, Australia, South Korea and Rest of Asia Pacific), Middle East & Africa (GCC, South Africa and Rest of MEA) and South America (Brazil, Argentina and Rest of South America) |
|
Key Developments |
June 2017: Genmab received the US FDA approval for Darzalex, for the relapsed or refractory multiple myeloma. |
|
Companies Covered |
Genmab A/S, GlaxoSmithKline, Bristol Myer Squibb, Novartis AG, Roche, and Celegene Corporation, among others. |
|
Report Offerings |
Acute Myeloid Leukemia Market offers latest trends, growth prospects, industry competitiveness, major players, regional share of market and forecast to 2023. |
Reasons to Purchase the Acute Myeloid Leukemia Market Report
- Current and future of Acute Myeloid Leukemia Market outlook in the developed and emerging markets
- Analysis of various perspectives of the market with the help of Porter’s five forces analysis
- The segment that is expected to dominate the market
- Regions that are expected to witness the fastest growth during the forecast period
- Identify the latest developments, market shares, and strategies employed by the major market players
- 3-month analyst support, along with the market estimate sheet (in Excel)
Customization of the Acute Myeloid Leukemia Market Report
- This report can be customized to meet your requirements. Please connect with our representative, who will ensure you to get a report that suits your needs.
1. Introduction
1.1 Market Definition
2. Research Methodology
3. Executive Summary
4. Key Inferences
5. Market Overview
5.1 Current Market Scenario
5.2 Porter’s Five Forces Analysis
5.2.1 Bargaining Power of Suppliers
5.2.2 Bargaining Power of Consumers
5.2.3 Threat of New Entrants
5.2.4 Threat of Substitute Products and Services
5.2.5 Competitive Rivalry within the Industry
6. Drivers, Restraints, Opportunities, and Challenges Analysis (DROC)
6.1 Market Drivers
6.1.1 High Incidence and Prevalence of Acute Myeloid Leukemia
6.1.2 Increasing Investment in Research and Development
6.1.3 Advancement in Pharmacology and Molecular Biology to Promote Drug Development
6.2 Market Restraints
6.2.1 Complications Related to Chemotherapy
6.2.2 Stringent Regulatory Guidelines of Governments
6.3 Opportunities
6.4 Key Challenges
7. Market Segmentation
7.1 By Chemotherapy
7.1.1 Cytarabine
7.1.2 Anthracycline Drugs
7.1.2.1 Daunomycin
7.1.2.2 Idarubicin
7.1.2.3 Mitoxantrone
7.1.3 Alkylating Agents
7.1.4 Anti-metabolites
7.1.5 Tyrosine Kinase Inhibitors
7.1.5.1 Dasatinib (Sprycel)
7.1.5.2 Imatinib (Gleevec)
7.1.6 Hormonal Therapy
7.1.7 Others
7.2 By Geography
7.2.1 North America
7.2.1.1 United States
7.2.1.2 Canada
7.2.1.3 Mexico
7.2.2 Europe
7.2.2.1 France
7.2.2.2 Germany
7.2.2.3 United Kingdom
7.2.2.4 Italy
7.2.2.5 Spain
7.2.2.6 Rest of Europe
7.2.3 Asia-Pacific
7.2.3.1 China
7.2.3.2 Japan
7.2.3.3 India
7.2.3.4 Australia & New Zealand
7.2.3.5 South Korea
7.2.3.6 Rest of Asia-Pacific
7.2.4 Middle East & Africa
7.2.4.1 GCC
7.2.4.2 South Africa
7.2.4.3 Rest of Middle East & Africa
7.2.5 South America
7.2.5.1 Brazil
7.2.5.2 Argentina
7.2.5.3 Rest of South America
8. Competitive Landscape
8.1 Merger & Acquisition Analysis
8.2 Agreements, Collaborations, and Partnerships
8.3 New Product Launches
9. Company Profiles
9.1 Celegene Corporation
9.2 Novartis AG
9.3 Genmab A/S
9.4 Eisai Co. Ltd.
9.5 Sanofi-Aventis (Genzyme Corporation)
9.6 Teva Pharmaceutical (Cephalon Inc.)
9.7 Pfizer Inc
9.8 Bristol Myer Squibb
9.9 Sunesis
10. Future of the Market
